ZEUS Names New President and CEO see more
Frank P. Tourville, Sr., Founder and Chairman of the Board of Zeus Industrial Products, Inc. announced on Wednesday, July 1, 2020 that Steve Peterson, President of Zeus, assumed the role of Chief Executive Officer. This organizational change comes with the recent retirement of former CEO, John Winarchick, who dedicated over 30 years of service to the company.
Peterson, who joined Zeus in 2017, previously held the position of Senior Vice President of Global Sales and Marketing. Before joining Zeus, Peterson held global leadership positions with TE Connectivity, Samsung Electronics, and General Electric. During that time, he assumed roles of increasing responsibility in sales, marketing, product management, supply chain management, and executive management.
As President and CEO of Zeus, Peterson will continue to play an instrumental role in leading the company forward by focusing on developing powerful growth strategies and providing ongoing value to customers, team members, and the surrounding communities. His invaluable contributions have already helped to shape the company Zeus is today.
“Steve Peterson has shown the true measure of a leader in unprecedented times of difficulty. His charisma, resilience, dedication, and vast industry knowledge are huge assets to Zeus,” said Frank P. Tourville, Sr., Founder and Chairman of the Board, Zeus Industrial Products, Inc.
Vikor Scientific featured in Charleston, Columbia and Greenville Business magazines see more
A number of South Carolina-based life sciences companies joined the battle against COVID-19 when the pandemic hit in early March. Prominent among this group is Charleston-based Vikor Scientific, a testing laboratory founded just over two years ago by entrepreneurs Shae Harrelson and Scotty Branch.
Vikor developed a COVID-19 test kit that is now widely used by nursing homes and other healthcare facilities across the nation. The test kit also tests for more than 40 other pathogens known to cause respiratory illness. Click to enjoy the entire article...
DPX supporting higher education institutions and research facilities see more
DPX Technologies, a manufacturer of laboratory consumable products for sample preparation, has awarded over $400,000 to researchers over the last several years. This amount is a combination of product donated and money awarded for researchers to use towards travel and presentations for industry specific scientific tradeshows or publications. DPX products have been featured in scientific publications including: Journal of Analytical Toxicology, Journal of Analytical and Bioanalytical Chemistry, and Journal of Chromatography.
DPX manufactures patented sample preparation products and specializes in custom workflows for a diverse client base. The INTipTM products have attracted the attention of researchers for years. “We often get contacted by researchers that want to develop and publish new methods that use our technology. We welcome that collaboration,” says Dr. Kaylee Mastrianni.
DPX wants to take a formalized approach in supporting higher education institutions and research facilities by awarding research grants to support the use of INTip sample preparation products as tools for education or discovery. DPX now has a form on their website to apply for research grants.
Grants will be awarded based on the novelty and scientific impact of the research described in the application. Applications will be reviewed on a rolling basis throughout the year by the DPX scientific review board and recipients can be awarded up to $1000 per year. DPX Technologies will notify the winners by email and/or telephone. Multiple forms may be submitted by the same applicant, college/university or facility as long as the need demonstrated is for different applications.
Monday Moment for June 29, 2020 see more
SCBIO's latest Monday Moment arrives amidst the COVID-19 storm to provide meaningful and inspiring information in 3 minutes or less. This week, enjoy an uplifting reminder from Kathryn Becker of Translational Science Solutions... plus lots of uplifting news... get details here
Good news for investment opportunities in the Palmetto State see more
South Carolina’s General Assembly renewed the 2013 High Growth Small Business Job Creation or “Angel Investor” Act earlier this week until 2025.
The act offers tax credits of up to 35% of the investment to start-up investors, according to a recent announcement from the S.C. State Secretary Mark Hammond. Hammond’s office, which approves all businesses for the program.
“Since the High Growth Small Business Job Creation Act originally passed, nearly 300 companies have registered as qualified businesses, with over 90 registered at the end of 2019,” Hammond, said in the release. “Furthermore, these qualified businesses have reported creating over 1,200 full-time, part-time and temporary jobs. I am thrilled that our state has continued this program that promotes innovation and entrepreneurship, especially during this time of economic uncertainty.”
Qualifying businesses must be a corporation, limited liability company, general or limited partnership headquartered in South Carolina with 25 or fewer employees and a gross income of $2 million or less, according to the release.
Program preference is extended to certain types of enterprises within the manufacturing, processing, warehousing, wholesaling, software development, information technology service, research and development, and health care sectors.
SCRA funds organizations for their COVID work see more
In response to the COVID-19 pandemic, the South Carolina Research Authority (SCRA) and its investment affiliate, SC Launch, Inc. have dedicated an additional $1.5 million in funding to support businesses that are providing coronavirus-related solutions and to help their current portfolio companies continue to meet their financial goals during this time.
Companies receiving funding to provide COVID-19 solutions are:
- Blue Eye Soft (COVID-19 detection and diagnosis)
- Carolina Diagnostic Solutions (pulmonary self-monitoring tools)
- Citibot (citizen engagement solution)
- Elastrin Therapeutics (treatment of lung-related illnesses)
- Pure Aqua Solution (destruction of pathogens including COVID-19)
- Precision Genetics (COVID-19 testing)
- Resiliency Technology, Inc. dba SHARPEN (mental health support for healthcare workers)
- Zylö Therapeutics (treatment of COVID-19 and other lung related illnesses)
Additional companies have received investments to help them continue growing their companies in spite of the pandemic. These are:
- ActiveEd (Walkabout app promoting learning and physical activity)
- BandwagonFanClub (fan demographic reporting to elevate event experiences)
- Ellipsis Technologies (anti-fraud and other cybersecurity tools)
- Global Transplant Solutions (organ preservation products)
- PEC360 (patient experience software)
- REsimplifi (commercial real estate property search)
“Our mission of fueling South Carolina’s innovation economy includes answering the call to help during this COVID-19 pandemic. Many of our current client companies were already providing or developing solutions related to COVID-19 while others quickly pivoted to address the pandemic. We are proud to be able to provide the support necessary to maximize the impact of these solutions,” said Bob Quinn, Executive Director of SCRA.
In addition to investing financially, SCRA is also involved in other initiatives to help fight the COVID-19 pandemic. Staff members are serving on various taskforces and committees with health systems and economic development organizations. Other SCRA-supported companies are providing solutions to the pandemic including Modjoul, which has developed an employee health screening platform, Humimic Medical and ZVerse, which are producing protective shields, and Vikor Scientific, which is providing respiratory pathogen testing. Lastly, SCRA is sharing COVID-19 resources online and through social media.
Chartered in 1983 by the State of South Carolina as a public, nonprofit corporation SCRA is a state-chartered organization that fuels job creation and grows South Carolina’s innovation economy. Through SCRA’s programs, SC Academic Innovations, SC Facilities, SC Launch and SC Ventures, researchers, developers and early-stage companies are receiving mentoring and funding, and may be eligible for an investment from SCRA’s investment affiliate, SC Launch, Inc.
KIYATEC Advancing Functional Ex Vivo 3D Cell Culture Models that Reveal Response Dynamics to Immuno-Oncology DrugsKey evidence to be presented at AACR 2020 see more
KIYATEC, Inc. today announced that it will present data at the 2020 American Association for Cancer Research (AACR) Annual Meeting, June 22-24, revealing how its 3D cell culture models characterize ex vivo tumor response and immunoreactivity to immune checkpoint inhibitors (i.e. PD-1, PD-L1 inhibitors) in solid tumors. These emerging capabilities address a significant unmet need in both preclinical drug development and clinical decision-making in oncology.
PD-1/L1 inhibitors have experienced meteoric growth over the last decade, offering hope to hundreds of thousands of cancer patients every year in the US alone. However, typically no more than 25-30% of eligible cancer patients who receive PD-1/L1 inhibitors actually respond to them. Given that the direct costs associated with PD-1/L1 therapy can run into the hundreds of thousands of dollars per patient, KIYATEC believes that pre-treatment, patient-specific PD-1/L1 response prediction could one day offer clinicians, patients and payers a more objective basis for determining PD-1/L1 inhibitor patient eligibility vs. today’s commonly used population-based biomarkers.
Evidence presented by KIYATEC at AACR 2020 will highlight findings of the company’s ability to detect dose-dependent response to checkpoint blockade and corresponding correlation with immune cell activation in high-throughput ex vivo 3D tumor spheroid models. KIYATEC believes these recent advances may represent key building blocks toward the eventual development and validation of clinical assays capable of accurate pre-treatment, patient-specific prediction of response to immuno-oncology drugs.
“We’re constantly innovating and expanding the capabilities of our 3D cell culture technologies to reduce the cost and risk of preclinical drug development for our immuno-oncology customers,” said Matthew Gevaert, CEO of KIYATEC. “As we continue to make these advances in immuno-oncology drug response on higher-throughput platforms, we can begin to envision a time when such capability would inform clinical decision-making for cancer patients as well.”
KIYATEC’s poster presentations at AACR 2020 are as follows:
- Abstract: 7397 / Poster: 315 / Session: 3D & Tissue Recombinant Models / June 22-24
Title: PARP inhibition in combination with pembrolizumab enhances cytotoxicity in ovarian cancer patient-derived 3D spheroids
- Abstract: 7132 / Poster: 2244 / Session: Immune Checkpoints 2 / June 22-24
About KIYATEC, Inc.
KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit www.kiyatec.com.
SCBIO Newsletter - Mid-June 2020: SC Leaders Weigh In June 23 on Securing State's Future Post-COVID & More!Important SC life sciences news and updates from SCBIO see more
Don't miss this latest issue of SCBIO's semi-monthly newsletter, chock full of great articles, events, updates, connections, resources and more.
Nephron steps up to support USC's planned reopening with donations of sanitizer see more
Nephron Pharmaceuticals Corp. is donating more than 100,000 bottles of company-manufactured hand sanitizer to the University of South Carolina as part of the West Columbia-based company's ongoing efforts to help fight COVID-19.
The first 5,000 bottles arrived on campus today, hand-delivered by Nephron president and CEO Lou Kennedy and Nephron's new van bearing its clinical lab logo to a group of student leaders on the university’s Horseshoe.
“No matter how tall the challenge is, Gamecocks step up,” Kennedy, a 1984 USC graduate, said in a news release. “Our company is proud to do our part to help the university make sure it is ready to welcome students, staff and faculty back to campus.”
USC, which closed its campuses in March in response to the COVID-19 pandemic, is resuming in-person instruction in mid-August.
“We’re grateful to Lou and Bill Kennedy and the entire team at Nephron Pharmaceuticals for this generous gift,” Bob Caslen, USC president, said. “This donation helps support the safe return of our students and employees to campus and exemplifies what the Gamecock spirit is all about: making our communities better through selfless service and caring for others.”
The bottles bear a private label requested by the university, Kennedy said.
Nephron develops and produces generic respiratory medication, including inhalation solutions and suspension products that can be used to treat severe respiratory symptoms associated with COVID-19.
In March, Nephron began making its own hand sanitizer, and previously donated 50 liters to the William Jennings Bryan Dorn Veteran Affairs Medical Center. The company added a production line in April be used in the manufacturing of bronchodilator albuterol as demand for its products soars during the pandemic.
Last month, the company announced an expansion of its COVID-19 testing capabilities through a partnership with medical technology company One Medical. Kennedy told the Columbia Regional Business Report today that Nephron’s on-site clinical lab began testing company employees last week and plans to process samples collected during a drive-thru testing clinic June 19 and 20 at Benedict College’s football stadium.
“We are trying to be a good partner with DHEC, a good partner with the local hospitals, and see how we can take some of the stress off of their labs for testing,” said Kennedy, who said Nephron has also developed, in partnership with Lexington Medical Center, a transport medium for nasal swabs used in the testing process.
Nephron has hired its own nurse practitioner and installed a chief medical officer, Kennedy said. She said the department-by-department testing of employees will continue through this week.
“The more we test, we’re going to find people that are asymptomatic, but it’s important for us to get this contact tracing thing figured out, get a baseline, get people home and get them well,” she said.
DPX publishes new application note see more
DPX recently published a new application note “Automated Method for High-Throughput LC-MS/MS Quantitation of Testosterone from Serum: An Improved Validated Method” where a new ultra pure grade filtration tip was introduced. The method for the extraction of testosterone from serum used Low Porosity Filtration Tips- Ultra Pure (LPFT-UP) and incorporated a ZnSO4 solution in addition to acetonitrile on a Hamilton Heater Shaker (HHS) for improved recovery and precision during protein precipitation. The LPFT-UP provide a high purity filtration media for methods with very low detection limits.
Patient samples had a calculated recovery of testosterone at 99.5% with no detected matrix effects. This demonstrates that the use of ZnSO4 and acetonitrile is very efficient in extracting testosterone, and the use of ultra pure grade tips (LPFT-UP) resulted in negligible losses. The introduction of Low Porosity Filtration tips- Ultra Pure provides a new product for low detection level methods.
“We are really excited to expand our product offering for steroid testing,” said Carmen Adamson, brand manager. DPX plans to expand on the research and development to include a full panel of steroids. “Testosterone imbalance can signal a problem in both men and women. This method provides an accurate and precise tool to aid in that determination,” said Evan DiVirgilio, application scientist. DPX continues to provide methods for efficient sample processing for clinical and forensic laboratories.
DPX Technologies manufactures patented sample preparation products and specializes in custom workflows for a diverse client base including clinical, forensic, food safety, and pharmaceutical industries. Their products offer INTip™ sample preparation solutions that are compatible with semi-automated and fully automated liquid handling systems. This enables high sample throughput and high laboratory efficiency.
# # #
About DPX Technologies
DPX is committed to providing innovative sample purification solutions. We collaborate with our customers to provide the high-quality products they need for complex chemical and biological analysis.
Okra Medical donates face masks to 8 hospitals see more
Okra Medical, a life sciences start-up company based on Johns Island, South Carolina, donated nearly 100,000 healthcare face masks to eight hospitals and one pediatric group serving on the frontlines of the COVID-19 pandemic. The majority of the masks are smaller in size to benefit children and young adults.
“Like many in America, the coronavirus brought our business to a standstill,” said Marshall Hartmann, CEO, Okra Medical. “We redirected our laboratory efforts to securing medical supplies to both help fund our payroll and to give back to our community.”
Okra Medical had planned to launch the company’s new pharmaceutical drug destroyer, SafeMedWaste in mid-March. Then COVID-19 hit. The leadership team started looking for ways to leverage their international relationships to support the company and the community. They landed on securing PPE for the healthcare industry.
“We are overwhelmed with gratitude for the waves of donations received from the Charleston community. Most donors have said that they don’t need or want any thanks, they just want to help in any way they can, and assisting them by providing an avenue to receive has been an honor. As we try to stay focused and rise to the strategic challenges we’re all being faced with, the impact these donations are having, on both a personal and national level, is incredible.” Jennifer Simon, MUSC.
MUSC is one of eight hospitals benefiting from Okra Medical’s donations. The full list is:
- Medical University of South Carolina, Charleston, SC
- Roper St. Francis Healthcare, Charleston, SC
- Coastal Pediatric Associates, North Charleston, SC
- Prisma Health, Greenville, SC
- Shriners Hospital for Children, Greenville, SC
- Conway Medical Center, Conway, SC
- WakeMed Children’s Hospital, Raleigh, NC
- Cincinnati Children's Hospital Medical Center, Cincinnati, OH
- University of Pittsburgh Medical Center Children’s Hospital, Pittsburg, PA
“We are thankful for the health care heroes willing to serve at a time like this,” said Hartmann. “Giving back is the easy part. U.S. Senator Tim Scott’s Office and SCBIO made donating even easier by providing helpful guidance to match donors with organizations in need.”
“The rapid response of Senator Tim Scott’s team allowed us to quickly get donation masks into the hands of people who needed them most,” said Justin Stas, Chief Technical Officer, Okra Medical. “We are very proud of the way our South Carolina community, from government to individuals, has come together during this difficult time.”
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has more than 675 firms, including Okra Medical, directly involved and 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.
“We continue to be humbled by the amazing and impactful response to this public health crisis by SCBIO stakeholders like Okra Medical. Their gracious donation of thousands of critically important pediatric healthcare face masks to help ensure the safety of children in hospital environments during this global pandemic is a great example of Okra’s culture of servant leadership combined with their business expertise and innovativeness. We’re very proud and grateful that they are a highly engaged member of our organization,” said Sam Konduros, President/CEO of SCBIO.
A member of SCBIO, Okra Medical has developed and validated a patented product called SafeMedWaste that will simplify the way pharmaceutical manufacturers, hospitals, and individuals destroy and dispose of highly-addictive controlled substances like opioids. To learn more about the environmentally-friendly product, watch this video on the company website.
About Okra Medical Inc.
Okra Medical, Inc., headquartered in Johns Island, South Carolina, specializes in product development, manufacturing and strategic sourcing of controlled pharmaceutical substance disposal solutions. Founded in 2018, the Company’s mission is to improve public health. Its best-in-class suite of SafeMedWaste products use single formulas that are fully compliant with DEA regulations requiring non-retrievable destruction of controlled substances. Okra Medical is a strategic sourcing partner to hospitals, hospice facilities, law enforcement agencies, pharmaceutical manufacturers, and veterinary care clinics. Visit www.okramedical.com.
South Carolina Launches COVID-19 Emergency Supply Portal to Connect Providers with Organizations in NeedSouth Carolina launches portal to connect critical supplies with those who need them see more
SCMEP, South Carolina Hospital Association, SC Department of Commerce and SCBIO combine
to source critical medical supplies and get them to parties in need quickly
South Carolina – April 13, 2020 – A collaboration between SCMEP, the SC Hospital Association, the SC Department of Commerce and SCBIO has resulted in the expedited launch of a new online South Carolina Emergency Supply Collaborative web portal.
Located at www.SCCOVID19.org, the portal connects parties in need of essential supplies and equipment with those that can provide it in quickly and efficiently. It allows industry and community partners with the ability to quickly produce, source, test, certify or contribute critical medical supplies (such as face shields, gowns, ventilators and masks) to directly connect with the healthcare providers, first responders and members of industry in search of those essential supply needs in one easy step.
Manufacturers able to expand or pivot their production lines, suppliers and distributors with access to ready-made supplies, organizations able to donate supplies or personal protective equipment (PPE) can identify the supplies and equipment they can offer in the site’s central repository. Once quickly reviewed and vetted by a team from the collaborative, organizations in need of the materials will be digitally connected through the portal to secure their desired goods from providers directly.
The need for the portal was identified after members of the collaborative began individually fielding hundreds of calls from organizations in need of such supplies, said Chuck Spangler, President of the South Carolina Manufacturing Extension Partnership (SCMEP).
“Each of our respective organizations has strong and indelible positions as sources of information, connection and aid to our respective constituencies, so it was logical for those parties – whether hospitals or manufacturers, existing industry or life sciences organizations – to turn to us in time of need,” said Mr. Spangler. “After sharing among ourselves the flood of requests we were individually receiving and trying to manage, we determined that a combined approach would offer greatest value and efficiency for our state and its citizens, and the creation of the South Carolina COVID-19 Emergency Supply portal was quickly underway.”
The site identifies critical need items as evidenced by industry, healthcare, first responder and governmental audiences across the state, and allows organizations to quickly enter the type of goods they can provide or manufacture, quantities and production capacity, and supply chain needs or requirements. Once entered and vetted by the SCMEP team, inquiring parties seeking the goods will be connected to the providers through the portal. Organizations then conduct transactions and arrange and plan logistics directly.
“This is a joint effort to recruit community partners with ability to quickly source or provide needed medical supplies to support South Carolina’s COVID-19 response,” said Thornton Kirby, President and CEO of the SC Hospital Association. “South Carolina’s COVID-19 Emergency Supply website will save valuable time and effort in connecting those in need of goods with those who have them… at a time where every minute counts in saving lives and defeating this formidable virus.”
The COVID-19 Emergency Supply website will be updated constantly with new information and opportunities to support South Carolina emergency response efforts. It also links directly to individual websites of the four Collaborative partners, which each provide a host of resources, news, connections and relevant information for businesses and individuals.
“We are all in this together, and I am proud of the South Carolina business community’s continued response to serve our state during this unprecedented time,” said S.C. Secretary of Commerce Bobby Hitt. “The COVID-19 Emergency Supply Collaborative’s ability to connect manufacturers, suppliers and other organizations with the front-line medical personnel who need these critical items will serve as a valuable resource.”
Organizations and individuals can go online 24/7 to identify critical need items or to note what products they can provide or may need, said Sam Konduros, CEO of SCBIO. “We encourage every member of industry, if you have a product that is needed and which you can provide, produce, test, certify or donate, let us know that right now by completing the simple form on the site. And for organizations in need of such items, let us know that right away so that we can get connect you with parties who can help right now.”
Visit the new site at https://sccovid19.org/
A message from SCBIO's CEO see more
Unprecedented steps are being taken by all of us – businesses and families alike – as we collectively combat the Coronavirus global pandemic that is hitting far too close to home. What was once a news story unfolding in Wuhan, China, only a few months ago has now become a harsh reality right here in the Palmetto State.
As of today, South Carolina has well over 1,000 confirmed cases of COVID-19, and the death rate is starting to climb – and COVID-19 “hotspots” like New York and New Orleans clearly demonstrate how rapidly this situation can deteriorate if we fail to do our parts with regard to social distancing, hand washing, and adhering to the mandate to stay at home as much as possible. The economic hardships accompanying the healthcare impacts of this horrific virus are painfully real and will hit many companies and citizens without mercy. None of us will be untouched, and the toughest days are still ahead…
On a truly encouraging note, collaboration, cooperation, innovation, and goodwill are being displayed by our stakeholders. SCBIO is integrating our efforts and resources closely with numerous fellow associations, agencies and organizations on a simultaneous basis. The SC Department of Commerce, SC Hospital Association, SC Manufacturing Extension Partnership, and the SC Research Authority are only a few of our respected partners that we are working virtually with on a daily basis to do whatever is possible to address vital needs. This potentially catastrophic event is spurring amazing ideas and heroic efforts that will echo for decades to come.
The life sciences and healthcare industries are valiantly front and center as the beacons of hope for conquering this invisible foe. SCBIO is grateful to have a relevant role on the COVID-19 battlefield but is most humbled to see the brilliance and resourcefulness of the companies and organizations we support and represent. There are far too many examples to highlight, but we are so proud of large and small member companies like Nephron Pharmaceuticals, Vikor Scientific, Precision Genetics, Thorne, Abbott Labs, and Humimic that have fearlessly stepped-up, retooled, and refocused to rapidly create desperately needed solutions to arm clinicians and healthcare providers with vital tools they need to effectively carry out their mission to literally save lives – ranging from COVID-19 test kits to respiratory therapies to face shields.
In our role as the Palmetto State’s life sciences industry lead organization, SCBIO has aggressively pivoted our activities to adapt to the demands of the current crisis, making significant decisions to keep our focus where it needs to be – and to demonstrate prioritization of our own work program in a manner that directly relates with the realities that our state and nation are facing. We want and need to hear from you about your efforts – and anything we can do to help.
As meaningful as it is to gather and convene, until some point in the future, nobody needs to be talking about conferences or sponsorships – and the thought of gathering hundreds of people is almost unimaginable at present. Based on that unavoidable truth – and our commitment to be an impactful problem-solver in this crisis – our signature SCBIO Annual Conference has been shifted from its historical time frame of October (2020) to February 16-18, 2021 in Charleston. For SCBIO, it’s a significant and symbolic decision that we felt compelled to make now to demonstrate our conviction to remain focused on COVID-19 issues for as long as is necessary. Likewise, our quarterly board meeting has been rescheduled from April 8th to June 18th at Furman University, with the hope that we might be able to safely convene as we approach early Summer. Until then, all our meetings will be virtual through the blessings of technology.
In closing, SCBIO’s current focus will continue to be:
- Solving supply chain issues by linking life sciences solution providing companies with healthcare providers and clinicians as rapidly as possible
- Working collaboratively with complementary agencies and organizations to solve issues that are challenging our industry, as well as healthcare professionals on the front lines treating patients in need
- Seeking capital and offering support to companies that have novel solutions to combat COVID-19 – but need assistance to scale up
- Conducting weekly webinars on highly relevant topics and COVID-19-related issues to various targeted audiences, ranging from FDA navigation and compliance to small business assistance to leading-edge science-based updates regarding the Coronavirus
- Retrieving and disseminating substantive and data-based/critical information about COVID-19 and making it readily available on our website’s dedicated Coronavirus portal (www.scbio.org)
- Markedly increasing our overall communications by providing two newsletters per month, and launching a short update every week with our new Monday Moment series – featuring crucial updates and member companies that are making a difference, with a little inspiration on the side
- Maintaining a steady series of virtual meetings with companies and organizations across the state and beyond to continue building and advancing life sciences in South Carolina
- Pursuing new grants and funding for high-impact workforce, innovation, and economic development strategies that can directly contribute to our mission
- Honing our infrastructure and skill sets with the goal of becoming the most effective statewide life sciences industry organization in America
- And, finally… Helping whoever we can, whenever we can – as unforeseen opportunities continue to present themselves daily
It is easy for an atmosphere of fear and anxiousness to hang in the air at a time like this, and each of us will experience some of that on certain days in such an alien season of life. But we can’t give into that. We are strong individually, but infinitely stronger together…we need God and each other more than ever, and there truly is a unique opportunity during this to learn, grow, and become better.
Our planet depends on Life Sciences… What a privilege for all of us to be part of that. Let’s fight the battle courageously, together – and seize the opportunity that has been presented.
Wishing all of you health, safety, and peace – Godspeed,
#ONWARD #gamefaceon #TeamSC #SCHelps
David Zaas, M.D., named CEO for MUSC Health - Charleston Div. and Chief Clinical Officer for MUSC HealthDavid Zaas Named to executive post at MUSC see more
Patrick J. Cawley, M.D., CEO for MUSC Health and vice president for Health Affairs, University, named David Zaas, M.D., MBA, as the new chief executive officer, MUSC Health - Charleston Division, and chief clinical officer for MUSC Health. In these roles, Zaas will report directly to Cawley, who leads the entire MUSC Health statewide system. Following a national search, Zaas was recommended for this major leadership position by a search committee co-chaired by Prabhakar Baliga, M.D., chair, Department of Surgery, and Lisa Montgomery, MHA, MUSC executive vice president, Finance and Operations. Zaas is scheduled to join MUSC in July.
As the CEO of MUSC Health - Charleston, Zaas will lead the MUSC Hospital Authority in Charleston, including the MUSC Shawn Jenkins Children’s Hospital and Pearl Tourville Women’s Pavilion. He will oversee the executive leadership team of the MUSC Health - Charleston Division and serve on the MUSC Health System Council, as CEO of our flagship hospital. His responsibility as chief clinical officer will involve providing guidance and advice on health care system strategies.
“Dr. Zaas has a deep appreciation for academic medicine and its critical role in research and innovation,” Cawley said. “He has a history of leading and promoting successful collaboration among a university, practice plan and health system. In addition, he is a profound advocate for patient and family centeredness and has a demonstrated track record of leading clinical growth, financial success and top performance in quality and safety. We look forward to the many contributions he can make to our health system,” he added.
Prior to accepting his new role, Zaas served as president of Duke Raleigh Hospital since 2014. His previous leadership positions at Duke University in Durham, North Carolina, include: chief medical officer, Duke Faculty Practice Diagnostic Clinic; medical director, Duke University Hospital; vice chair, Department of Medicine, Duke University; and medical director for Lung and Heart-Lung Transplantation, Duke University Hospital. He has played a central role in advancing multiple key strategic initiatives for Duke Health, including care redesign, clinical integration and improving access for patients.
Zaas holds a B.A. in biology from Yale University, an M.D. from Northwestern University Medical School, and an MBA from Duke University. He completed his internal medicine residency at Johns Hopkins Hospital and fellowship in pulmonary and critical care at Duke University. Zaas’s academic interests have involved both translational and clinical research focused on improving outcomes from lung transplantation including the role of infectious complications after transplant.
About MUSC Health
As the clinical health system of the Medical University of South Carolina (MUSC), MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2019, for the fifth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.
Founded in 1824, MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care. For information on academic programs, visit musc.edu.
Nephron, Ritedose to the rescue with respiratory drugs see more
Two South Carolina companies that make drugs used to treat respiratory illnesses and symptoms, like those experienced by people infected with the coronavirus, have upped their production amid increased demand.
Nephron Pharmaceuticals in West Columbia and Ritedose Corp. make generic versions of almost all the respiratory drugs used in the United States, including albuterol sulfate and ipratropium bromide, according to the CEOs of the two companies.
Business at Nephron spiked last week, CEO Lou Kennedy said, with orders up 48 percent. The CEO of Ritedose, Jody Chastain, said his company has received a slight increase in demand. Click to read full story, courtesy of The Post and Courier...